Lectures

HMG-CoA Reductase Inhibitors – Lipid Control

by Pravin Shukle, MD
(1)

Questions about the lecture
My Notes
  • Required.
Save Cancel
    Learning Material 2
    • PDF
      Slides LipidPharmacology CardiovascularPharma.pdf
    • PDF
      Download Lecture Overview
    Report mistake

    About the Lecture

    The lecture HMG-CoA Reductase Inhibitors – Lipid Control by Pravin Shukle, MD is from the course Cardiovascular Pharmacology. It contains the following chapters:

    • HMG-CoA Reductase Inhibitors
    • HMG-CoA Reductase Inhibitors: Toxicity
    • HMG-CoA Reductase Inhibitors: Important Points
    • Cholesterol Transport Inhibitors: Ezetimibe

    Included Quiz Questions

    1. Protective against contrast nephropathy
    2. Increases LDL receptor expression
    3. Induction of CYP450 3A4 system
    4. Inhibition of cholesterol transporter
    5. Inhibits intracellular production of cholesterol
    1. Rhabdomyolysis risk is increased when combined with Ezitimibe
    2. They may produce mild elevation of CK levels
    3. They may produce mild elevations of transaminases
    4. Drug interactions may occur with inducers of CYP450 3A4 with simvastatin
    5. Cerivastatin was withdrawn from the market due to risk for rhabdomyolysis
    1. Pravastatin
    2. Cerivastatin
    3. Rosuvastatin
    4. Atorvastatin
    5. Fluvastatin
    1. Properly functioning LDL receptors are required for statins to produce their effect
    2. VLDL synthesis is impaired, so these patients have lower LDL levels already
    3. HMG-CoA reductase binding site is distorted in these patients making statins less effective
    4. The high risk of drug-induced pancreatitis precludes these patients from being prescribed statins
    5. These patients are deficient in lipoprotein lipase and rarely have elevated LDL levels
    1. There is no increase in the risk for hepatoxicity when combined with statins.
    2. It is a prodrug that requires glucuronidation to exert its biological effect
    3. It is one of the best tolerated drugs in the management of hyperlipidemia
    4. It acts by inhibiting the cholesterol transporter
    5. It results in a reactive increase in LDL receptors

    Author of lecture HMG-CoA Reductase Inhibitors – Lipid Control

     Pravin Shukle, MD

    Pravin Shukle, MD


    Customer reviews

    (1)
    5,0 of 5 stars
    5 Stars
    5
    4 Stars
    0
    3 Stars
    0
    2 Stars
    0
    1  Star
    0